Patients with malignant carcinoid tumours are cur¬ rently treated with somatostatin analogues, which reduce circulating hormone levels and related symp¬ toms (1, 2) . The (3) (4) (5) . It Patients were monitored after 1-3 months using the tumour markers U-5HIAA and chromogranin A: U-5HIAA (determined according to a method described earlier (7)) was calculated as the mean of two 24 h collections; the plasma chromogranin A level also was determined according to a method described previously (8) . An 
